What Researchers Did
Researchers treated 43 patients suffering from sudden sensorineural hearing loss or tinnitus with 10 sessions of hyperbaric oxygen therapy and assessed their serological levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).
What They Found
Among 43 patients, no sex- or age dependency was observed for basic fibroblast growth factor (bFGF) levels during hyperbaric oxygen therapy. The study aimed to investigate the impact of HBO on these growth factors, suggesting potential changes in vascular endothelial growth factor (VEGF) levels, though specific findings for VEGF are not fully detailed in the provided abstract.
What This Means for Canadian Patients
Understanding how hyperbaric oxygen therapy affects growth factors like bFGF and VEGF could help optimize its use for Canadian patients with conditions like chronic wounds or ischemic disorders. This knowledge may contribute to more effective treatment strategies by clarifying the biological mechanisms of HBO.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or participants.
Study Limitations
A limitation of this study is the relatively small sample size of 43 patients, which may limit the generalizability of the findings.